Tuesday 13 October 2026
Export ENTX’s income statement to Excel — free account
Entera Bio Ltd.
ENTX Healthcare Biotechnology
Entera Bio Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $42,000.00, down 76.8% from fiscal 2024. In the quarter to June 2026, revenue grew 200.0%, EPS fell 133.3% and free cash flow fell 108.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.51
0.14
−5.28%
Follow ENTX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 5 | 6 | 4 | — | — | — |
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Altman Z-Score |
— | — | (2.77) | (3.47) | (7.58) | 7.95 | (3.20) | — | 17.22 | 6.22 |
P/S ratio |
— | — | 0.00 | 35.32 | 54.49 | 129.07 | 219.28 | — | 409.32 | 401.84 |
Altman Z″-Score (non-manufacturers) |
— | — | (10.34) | (9.93) | (22.80) | (0.98) | (15.64) | — | (34.49) | (20.27) |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | 0.14 | (2.67) | (3.36) | 0.28 | — | — | — |
P/Operating CF |
— | — | (20.35) | (8.11) | (13.03) | (29.34) | (14.61) | — | (54.41) | (48.89) |
P/B ratio |
— | — | 4.73 | 2.18 | 2.65 | 3.27 | 2.50 | — | 9.88 | 6.84 |
Price to Tangible BV |
— | — | 5.06 | 2.30 | 2.67 | 3.27 | 2.51 | — | 9.94 | 6.86 |
EV/Sales |
— | — | 0.00 | 19.98 | 41.62 | 92.29 | 156.48 | — | 384.88 | 352.56 |
EV/EBITDA |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
EV/Operating CF |
— | — | (4.11) | (1.65) | (1.44) | (5.81) | (1.68) | — | (11.01) | (10.67) |
EV/FCF |
— | — | (4.08) | (1.64) | (1.43) | (5.79) | (1.67) | — | (10.99) | (10.51) |
Quick Ratio |
0.50 | 5.81 | 3.88 | 3.37 | 4.81 | 7.93 | 9.36 | 10.10 | 7.47 | 6.76 |
Current Ratio |
0.52 | 6.15 | 3.94 | 3.41 | 4.95 | 8.01 | 9.58 | 10.32 | 7.63 | 6.94 |
Net Debt/EBITDA |
(3.85) | 0.70 | 1.07 | 1.35 | 0.77 | 2.05 | 0.95 | 1.25 | 0.91 | 1.29 |
Debt/Assets |
409.66% | 29.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(1.02) | (0.12) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.04 | 0.02 | 0.03 | 0.03 | 0.01 | 0.00 | 0.02 | 0.00 |
Operating CF/Net income |
2.62 | 0.40 | 0.95 | 0.83 | 0.94 | 0.74 | 0.96 | 0.82 | 0.71 | 0.64 |
Capex/Depreciation |
— | (1.19) | (1.26) | (0.17) | (0.84) | (0.32) | (0.73) | (0.30) | (0.07) | (3.57) |
Interest Coverage |
(75.06) | — | — | — | — | — | — | — | — | — |
| 4.22% | 39.42% | 96.11% | (97.98%) | (115.46%) | (81.04%) | (76.17%) | (80.30%) | (103.34%) | (108.01%) | |
| (12.26%) | (114.47%) | (77.42%) | (71.86%) | (84.89%) | (68.26%) | (66.84%) | (71.42%) | (90.20%) | (90.13%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
24.42% | (105.59%) | (108.12%) | (95.99%) | (150.35%) | (54.59%) | (112.23%) | (86.59%) | (121.49%) | (86.47%) |
Average Days of Receivables |
— | — | 529.25 | 429.96 | 255.00 | 116.98 | 670.07 | — | 254.09 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 1,703.60% | 3,050.42% | 1,748.49% | 1,185.81% | 4,364.18% | 0.00% | 2,485.64% | 14,295.24% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 568.60% | 1,813.98% | 1,329.04% | 996.50% | 5,412.69% | 0.00% | 2,814.92% | 13,154.76% |
Intangible Assets out of Total Assets |
0.10 | 0.05 | 0.05 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 246.60% | 628.39% | 246.85% | 325.92% | 1,676.87% | 0.00% | 1,412.15% | 6,547.62% |
Graham Net Nets |
— | — | 0.19 | 0.42 | 0.35 | 0.30 | 0.39 | — | 0.10 | 0.14 |
Graham Number |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Earnings Yield |
— | — | (39.26%) | (41.59%) | (55.91%) | (16.54%) | (44.12%) | — | (11.79%) | (13.40%) |
Free Cash Flow Yield |
— | — | (20.61%) | (34.47%) | (53.34%) | (12.35%) | (42.70%) | — | (8.55%) | (8.34%) |
Revenue per Share |
0.00 | 0.00 | 0.06 | 0.02 | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.27) | (1.01) | (1.23) | (0.73) | (0.57) | (0.35) | (0.43) | (0.25) | (0.18) | (0.16) |
Capex per Share |
0.00 | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.27) | (1.02) | (1.24) | (0.74) | (0.58) | (0.35) | (0.44) | (0.25) | (0.18) | (0.16) |
Cash per Share |
0.45 | 2.62 | 1.45 | 1.25 | 0.47 | 0.95 | 0.43 | 0.38 | 0.23 | 0.32 |
Shareholders Equity per Share |
(2.17) | (7.03) | 1.27 | 0.98 | 0.41 | 0.86 | 0.41 | 0.36 | 0.21 | 0.28 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(2.17) | (7.03) | 1.27 | 0.98 | 0.41 | 0.86 | 0.41 | 0.36 | 0.21 | 0.28 |
Free Cash Flow |
(3.14) | (4.58) | (9.86) | (8.96) | (10.61) | (9.08) | (12.55) | (7.33) | (6.82) | (7.48) |
Working Capital |
(5.11) | 10.40 | 9.31 | 11.04 | 7.27 | 22.17 | 11.51 | 10.17 | 7.80 | 13.10 |
Capital Expenditures |
— | (0.05) | (0.07) | (0.04) | (0.05) | (0.02) | (0.05) | (0.02) | 0.00 | (0.11) |
Net Current Asset Value |
(26.10) | (32.42) | 9.24 | 10.85 | 6.90 | 21.91 | 11.48 | 9.88 | 7.66 | 12.41 |
EV/EBIT |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 0.14 | 0.17 | 0.15 | 0.03 | 0.35 | 0.00 | 0.02 | 2.55 |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 0.21 | 0.24 | 1.18 | 0.33 | 0.34 | 0.46 | 0.56 | 0.81 | 0.22 |
Cash ROIC |
(54.71%) | 28.75% | (45.59%) | (33.05%) | (65.89%) | (19.13%) | (52.14%) | (34.23%) | (40.75%) | (26.72%) |
Accounts Receivable Turnover |
— | — | 1.00 | 0.47 | 1.37 | 2.61 | 0.62 | — | 0.97 | 0.00 |
Accounts Payable Turnover |
0.11 | 0.13 | 0.00 | 0.52 | 1.20 | 2.26 | 1.10 | 0.00 | 1.60 | 0.14 |
Inventory Turnover |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Average Days of Payables |
552.71 | 5,059.07 | 0.00 | 580.52 | 199.53 | 162.44 | 61.44 | 0.00 | 280.12 | 3,893.33 |
Days of Inventory on Hand |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Average Receivables |
— | — | 0.50 | 0.50 | 0.27 | 0.22 | 0.21 | — | 0.19 | — |
Average Payables |
0.32 | 0.32 | 0.53 | 0.40 | 0.25 | 0.17 | 0.09 | 0.05 | 0.11 | 0.29 |
Average Assets |
9.78 | 9.78 | 13.31 | 15.02 | 13.21 | 17.85 | 19.56 | 12.45 | 10.58 | 12.69 |
Average Common Equity |
(28.40) | (28.40) | (10.72) | 11.02 | 9.71 | 15.04 | 17.16 | 11.07 | 9.23 | 10.59 |
Columns are period end dates